Fischer, Luca http://orcid.org/0000-0003-2444-416X
Jiang, Linmiao http://orcid.org/0000-0002-9009-4236
Dürig, Jan
Schmidt, Christian
Stilgenbauer, Stephan http://orcid.org/0000-0002-6830-9296
Bouabdallah, Krimo
Solal-Celigny, Philippe
Scholz, Christian W.
Feugier, Pierre
de Wit, Maike
Trappe, Ralf Ulrich
Hallek, Michael
Graeven, Ullrich http://orcid.org/0000-0001-6082-7710
Hänel, Mathias
Hoffmann, Martin
Delwail, Vincent
Macro, Margaret
Greiner, Jochen http://orcid.org/0000-0003-1256-173X
Giagounidis, Aristoteles A. N.
Dargel, Beate
Durot, Eric http://orcid.org/0000-0003-3463-0089
Foussard, Charles
Silkenstedt, Elisabeth
Weigert, Oliver http://orcid.org/0000-0002-0987-7373
Pott, Christiane http://orcid.org/0009-0005-9260-8340
Klapper, Wolfram
Hiddemann, Wolfgang
Unterhalt, Michael
Hoster, Eva http://orcid.org/0000-0002-0749-1389
Ribrag, Vincent
Dreyling, Martin
Funding for this research was provided by:
Janssen Pharmaceuticals
Roche
Bristol-Myers Squibb Company | Bristol-Myers Squibb Canada
AstraZeneca
Gilead Sciences
AbbVie
Amgen
Bristol-Myers Squibb
Celgene
GlaxoSmithKline
Eli Lilly and Company
Novartis
Acerta, BeiGene, Sunesis
Merck & Co., Inc. | MSD K.K.
Miltenyi Biotec
Takeda Pharmaceutical Company
Falk Foundation
Pfizer
Sanofi | Sanofi-Aventis Korea Company
Servier
Bayer
Article History
Received: 20 December 2023
Revised: 9 April 2024
Accepted: 10 April 2024
First Online: 27 April 2024
Competing interests
: JD served on advisory boards and received speakers’ honoraria from Janssen and Roche. C Schmidt received support for consultancy from BMS and Janssen, honoraria from BMS and Astra Zeneca and meeting or travel support from Kite Gilead. SS received advisory board honoraria, research support, travel support, speaker fees and support for trial participation from AbbVie, Acerta, Amgen, AstraZeneca, BeiGene, BMS, Celgene, Gilead, GSK, Hoffmann-La Roche, Janssen, Lilly, Novartis, Sunesis. C Scholz received consultancy fees from GILEAD, Incyte, Janssen-Cilag, MSD, Miltenyi Biotec, Novartis, Roche, Takeda, honoraria from BeiGene, GILEAD, Janssen-Cilag, Roche, Lilly, Takeda and travel expenses from BeiGene, Roche and Takeda. MH received honoraria from Novartis, Sobi, Gilead Sciences and Falk Foundation, has consulted for Novartis, BMS/Celgene, Gilead Sciences, Pfizer, Incyte, Sanofi/Aventis, Roche, Amgen, Sobi and Janssen. VR received research funding from Astex and GSK, consulting fees from Servier, honoraria from Abbvie and Pharmamar, meeting/travel support from AZD and GSK and participated on a Data Safety Monitoring Board or Advisory Board of BMS, AZD and Gilead. MD received research funding from Abbvie, Bayer, BMS/Celgene, Kite/Gilead, Janssen and Roche, speakers’ honoraria from Astra Zeneca, Beigene, Gilead/Kite, Janssen, Lilly, 1 Novartis and Roche, and served on scientific advisory boards of Abbvie, Astra Zeneca, Beigene, BMS/Celgene, Gilead/Kite, Janssen, Lilly/Loxo, Novartis and Roche. All remaining authors declare no competing financial interests.